METTL14

Across TCGA pan-cancer cohorts, METTL14 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated METTL14 data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher METTL14 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated METTL14 expression acts as an unfavorable survival marker.

LIHC, UCS, and UCEC are the cancer types where METTL14 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
UCS	OS	Median	All	0.185	0.686	.034	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	DFS	Median	All	0.140	0.666	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

METTL14–LIHC (DFS)

Open the LIHC breakdown →